Build and buy: Chr. Hansen's strategy to solidify its microbiome business

October 15, 2021 | Case Study

Chr. Hansen is a key player in the nutritional and health ingredients landscape. In particular, the company's human health and probiotics segment is well-known for developing and launching a number of key probiotic strains like Lactobacillus rhamnosus and Bifidobacterium, BB-12. Over the years, the company has focused on building its internal R&D expertise, and it has developed a robust technology platform for probiotics production. Since 2020, it has also made notable acquisitions for gut microbiome modulation, namely HSO Health Care and UAS Labs for probiotic products as well as Jennewein Biotechnologie on the prebiotics side for human milk oligosaccharides.